Keyphrases
Non-small Cell Lung Cancer (NSCLC)
70%
Advanced Gastric Cancer
70%
Lung Cancer
60%
Chemotherapy
58%
Cisplatin
54%
Progression-free Survival
52%
Irinotecan
47%
Monotherapy
44%
Older Men
37%
Immune Checkpoint Inhibitors
36%
Japan
36%
Overall Survival
36%
Small Cell Lung Cancer
31%
Fluoropyrimidine
30%
Median Progression-free Survival
30%
Docetaxel
29%
Lung Adenocarcinoma
29%
Tumor
29%
Hokushin Region
29%
Gastrointestinal Stromal Tumor
29%
Nivolumab
27%
Multi-institutional Survey
25%
5-fluorouracil (5-FU)
25%
Clinical Course
25%
Median Overall Survival
24%
Lung
23%
Immune Checkpoint Inhibitor Therapy
23%
Human Lung Fibroblasts
22%
Confidence Interval
22%
SRT1720
22%
Combination Chemotherapy
21%
Sirtuin 1 (SIRT1)
20%
Shakuyakukanzoto
20%
Endoscopic Ultrasound-guided Fine-needle Aspiration (EUS-FNA)
19%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
19%
Cancer Patients
19%
Phase II Study
19%
Adverse Effects
18%
Gastric Cancer
18%
Clinical Outcomes
18%
Metastatic Colorectal Cancer (mCRC)
18%
Endoscopic Submucosal Dissection
18%
Amrubicin
18%
Clinical Practice
18%
Interstitial Pneumonia
17%
Interleukin-6
16%
Oxaliplatin
16%
Prognostic Factors
16%
S-1 Plus Cisplatin
16%
Second-line Chemotherapy
15%
Lung Injury
15%
Multicenter Retrospective Study
15%
Response Rate
15%
Induced Apoptosis
15%
Preventive Effect
15%
First-line Chemotherapy
15%
Computed Tomography
14%
Pembrolizumab
14%
Mikulicz's Disease
14%
Mitomycin C
14%
Eosinophilic Pneumonia
14%
SIRT1 Activator
14%
Intra-aortic Balloon Occlusion
14%
Endoscopic Retrograde Cholangiopancreatography
14%
C-Jun N-terminal Kinase Signaling
14%
Photo-cross-linker
14%
Elderly Patients
14%
Bradykinin
14%
Stomach
14%
Bronchiolitis
14%
Ionizing Radiation
14%
Alveolar Epithelial Cells
14%
Franseen Needle
14%
Interleukin-8
14%
Ulcer
14%
Endoscopic Hemostasis
14%
Liver Metastasis
14%
Clinical Trials
13%
Diarrhea
13%
Epidermal Growth Factor Receptor
13%
Tumor Cells
13%
Multivariate Analysis
13%
Performance Status
13%
Anemia
13%
Adverse Events
12%
Paclitaxel
12%
Pancreas
12%
MRNA Level
12%
Carboplatin
12%
Gastrointestinal Cancer
12%
Lung Cancer Patients
12%
Older Women
12%
UGT1A1
12%
Japanese Patients
12%
Patient Characteristics
12%
Programmed Death-ligand 1 Expression
12%
Retrospective Analysis
12%
Immune-related Adverse Events
11%
Male Patients
11%
Home Death
11%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Abdominal Cancer
75%
Progression Free Survival
74%
Overall Survival
62%
Cisplatin
54%
Non Small Cell Lung Cancer
54%
Retrospective Study
53%
Irinotecan
48%
Adverse Event
47%
Monotherapy
45%
Small Cell Lung Cancer
43%
Immune Checkpoint Inhibitor
39%
Neoplasm
37%
Lung Cancer
36%
Epidermal Growth Factor Receptor
36%
Fluoropyrimidine
30%
Docetaxel
28%
Fluorouracil
23%
Disease
22%
N [2 [3 (1 piperazinylmethyl)imidazo[2,1 B]thiazol 6 Yl]phenyl] 2 Quinoxalinecarboxamide
22%
Oxaliplatin
20%
Messenger RNA
19%
Paclitaxel
18%
Metastatic Colorectal Cancer
18%
Combination Therapy
17%
Nivolumab
17%
Protein P53
16%
Interleukin 6
16%
Programmed Death 1 Ligand 1
16%
Amrubicin
16%
Clinical Trial
16%
Pancreas Cancer
15%
Phosphotransferase
15%
Mitomycin
14%
Ionizing Radiation
14%
Gastrointestinal Stromal Tumor
14%
Neuroendocrine Carcinoma
14%
Imatinib
14%
Bradykinin
14%
Interleukin 8
14%
Recurrent Disease
14%
Diarrhea
14%
First-Line Chemotherapy
14%
Cytokine
13%
Second-Line Chemotherapy
13%
Malignant Neoplasm
13%
Inflammation
13%
Cetuximab
12%
Asthma
12%
Pembrolizumab
12%
Lactate Dehydrogenase
11%
Folinic Acid
11%
Ramucirumab
11%
Neurotoxicity
11%
Disease Course
9%
Gemcitabine
9%
Acute Pancreatitis
9%
Durvalumab
9%
Hydrogen Peroxide
9%
Epidermal Growth Factor Receptor Kinase Inhibitor
9%
Bevacizumab
8%
Colorectal Carcinoma
8%
Liver Metastasis
8%
Inflammatory Bowel Disease
8%
Pancreatitis
8%
Injury
8%
Radiation Pneumonia
8%
Breast Cancer
7%
Carcinoma
7%
Neutropenia
7%
Crohn's Disease
7%
Liver Cell Carcinoma
7%
Glutamate Sodium
7%
Squamous Cell Lung Carcinoma
7%
Immunoglobulin A
7%
Multidrug Resistance Associated Protein 1
7%
Diphtheria Toxin
7%
Infliximab
7%
Mercaptopurine
7%
Chronic Obstructive Lung Disease
7%
Gamma Urogastrone
7%
Pleura Mesothelioma
7%
CagA Protein
7%
Creatinine
7%
Gelatinase A
7%
Fatty Liver
7%
Isoprenaline
7%
Stag
7%
Doxorubicin
7%
Tumor Necrosis Factor Inhibitor
7%
Digestive System Cancer
7%
Legionella
7%
Cystatin C
7%
Vasculitis
7%
Daptomycin
7%
Sunitinib
7%
Colorectal Liver Metastasis
7%
Coumarin
7%
Peritoneum Metastasis
7%
Carnitine
7%
Medicine and Dentistry
Lung Cancer
68%
Chemotherapy
52%
Lung
49%
Non Small Cell Lung Cancer
43%
Abdominal Cancer
42%
Immune Checkpoint Inhibitor
40%
Neoplasm
38%
Retrospective Study
30%
Disease
30%
Progression Free Survival
29%
Lung Adenocarcinoma
29%
Malignant Neoplasm
28%
Small Cell Lung Cancer
28%
Overall Survival
28%
Nivolumab
27%
Computer Assisted Tomography
26%
Disease Course
24%
Arm
21%
Ulcer
21%
Pancreas Cancer
21%
Endoscopic Ultrasound Guided Fine Needle Biopsy
20%
Epidermal Growth Factor Receptor
20%
Endoscopic Submucosal Dissection
18%
Recurrent Disease
17%
Idiopathic Interstitial Pneumonia
17%
Bronchiolitis
17%
Monotherapy
16%
Tumor Cell
15%
Adverse Event
15%
Diagnosis
15%
Metastatic Carcinoma
15%
Löffler's Syndrome
14%
Endoscopic Ultrasound
14%
Fine-Needle Aspiration
14%
Immunoglobulin G4
14%
Mikulicz Disease
14%
Endoscopic Retrograde Cholangiopancreatography
14%
Balloon Occlusion
14%
Endoscopic Hemostasis
14%
Epithelial Cell
14%
Sirtuin1
14%
Prednisolone
14%
Pembrolizumab
14%
Liver Metastasis
13%
Biopsy Technique
12%
Bleeding
12%
Bronchiolitis Obliterans Organizing Pneumonia
12%
Helicobacter Pylori
11%
Patient Characteristics
11%
Immunity
11%
Irinotecan
11%
Gemcitabine
11%
Surgery
11%
Endoscopy
11%
Cisplatin
11%
Evans Syndrome
11%
Small-Cell Carcinoma
11%
Carboplatin
11%
Cancer
10%
Messenger RNA
10%
Dyspnea
10%
T-Helper Cell
10%
Lung Carcinoma
10%
Multivariate Analysis
10%
Thorax Radiography
10%
First-Line Chemotherapy
10%
Prognostic Factor
10%
Adenocarcinoma
9%
Fibrosis
9%
Symptomatic Treatment
9%
Scintigraphy
9%
Protein P53
9%
Duodenum
9%
Combination Chemotherapy
9%
Radiofrequency Ablation
9%
Amino Terminal Sequence
9%
Blood Pressure
9%
Cancer Cell
9%
Immunohistochemistry
9%
Neutrophil
9%
Lymphocyte
9%
Systemic Therapy
8%
Loss of Appetite
8%
Immune-Related Adverse Events
8%
Immunoglobulin Producing Cell
8%
Pleura Mesothelioma
8%
Comorbidity
8%
Cellular Infiltration
8%
Ischemic Heart Disease
8%
Clinical Trial
8%
Provocation Test
8%
Lactate Dehydrogenase
8%
Upregulation
8%
Nonsteroid Antiinflammatory Agent
8%
Radiation Pneumonia
8%
Gefitinib
7%
Meningeal Carcinomatosis
7%
Cancer Staging
7%
Carcinoma
7%
Supportive Care
7%